|
|
||||||||


*
Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
Deficiencies in C factors C2, C3, or C4 as well as lack of C receptors 1 and 2 (CR1/2) lead to impaired Ab production. Classical pathway activation plays a major role, as mice deficient in factor B, a key factor in the alternative pathway, have normal Ab production. Abs in complex with their specific Ag are known to feedback regulate the Ab response, and enhanced responses are initiated by IgM, IgE, and IgG. IgM acts via the C system, whereas IgE and IgG can operate independently of C via Fc receptors. Here we have investigated whether these isotypes are able to enhance Ab responses in mice lacking CR1/2. SRBC-specific IgM, administered with SRBC, does not enhance Ab responses in these animals. In contrast, 2,4,6-trinitrophenyl-specific IgE and IgG2a, administered with BSA-2,4,6-trinitrophenyl, induce potent Ab responses in CR1/2-deficient mice. Additionally, BSA administered with CFA or alum induced strong Ab responses in the absence of CR1/2. These results indicate that CR1/2 is needed to promote IgM-mediated induction of primary Ab responses. The data also show that the need for CR1/2 can be circumvented by Abs typical of a secondary immune response forming complexes with Ag or by conventional adjuvants, presumably mimicking physiological inflammatory reactions.
This article has been cited by other articles:
![]() |
F. Hjelm, M. C. I. Karlsson, and B. Heyman A Novel B Cell-Mediated Transport of IgE-Immune Complexes to the Follicle of the Spleen J. Immunol., May 15, 2008; 180(10): 6604 - 6610. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Getahun, F. Hjelm, and B. Heyman IgE Enhances Antibody and T Cell Responses In Vivo via CD23+ B Cells J. Immunol., August 1, 2005; 175(3): 1473 - 1482. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Whipple, R. S. Shanahan, A. H. Ditto, R. P. Taylor, and M. A. Lindorfer Analyses of the In Vivo Trafficking of Stoichiometric Doses of an Anti-Complement Receptor 1/2 Monoclonal Antibody Infused Intravenously in Mice J. Immunol., August 15, 2004; 173(4): 2297 - 2306. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Getahun, J. Dahlstrom, S. Wernersson, and B. Heyman IgG2a-Mediated Enhancement of Antibody and T Cell Responses and Its Relation to Inhibitory and Activating Fc{gamma} Receptors J. Immunol., May 1, 2004; 172(9): 5269 - 5276. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rossbacher and M. J. Shlomchik The B Cell Receptor Itself Can Activate Complement to Provide the Complement Receptor 1/2 Ligand Required to Enhance B Cell Immune Responses In Vivo J. Exp. Med., August 18, 2003; 198(4): 591 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. de Stahl, J. Dahlstrom, M. C. Carroll, and B. Heyman A Role for Complement in Feedback Enhancement of Antibody Responses by IgG3 J. Exp. Med., May 5, 2003; 197(9): 1183 - 1190. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |